These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 6896025)
1. The effect of renal function on changes in circulating concentrations of 1,25-dihydroxycholecalciferol after an oral dose. Papapoulos SE; Clemens TL; Sandler LM; Fraher LJ; Winer J; O'Riordan JL Clin Sci (Lond); 1982 Apr; 62(4):427-9. PubMed ID: 6896025 [TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
3. Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis. Papapoulos SE; vd Berg H; Frölich M; Valentijn RM Nephrol Dial Transplant; 1988; 3(5):647-50. PubMed ID: 3146722 [TBL] [Abstract][Full Text] [Related]
5. Extrarenal production of calcitriol in normal and uremic humans. Dusso AS; Finch J; Brown A; Ritter C; Delmez J; Schreiner G; Slatopolsky E J Clin Endocrinol Metab; 1991 Jan; 72(1):157-64. PubMed ID: 1986015 [TBL] [Abstract][Full Text] [Related]
6. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016 [TBL] [Abstract][Full Text] [Related]
7. Single-dose oral calcitriol and changes of plasma 1,84iPTH in uremic children. Klaus G; Schmidt-Gayk H; Roth HJ; Ritz E; Mehls O Adv Perit Dial; 1994; 10():261-6. PubMed ID: 7999841 [TBL] [Abstract][Full Text] [Related]
8. 1,25-dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: effects of simultaneous protein and phosphorus restriction. Lucas PA; Brown RC; Woodhead JS; Coles GA Clin Nephrol; 1986 Jan; 25(1):7-10. PubMed ID: 3754187 [TBL] [Abstract][Full Text] [Related]
9. Vitamin D3 metabolites in chronic renal failure and after renal transplantation. Lucas PA; Woodhead JS; Brown RC Nephrol Dial Transplant; 1988; 3(1):70-6. PubMed ID: 3132643 [TBL] [Abstract][Full Text] [Related]
10. The effect of the dihydroxylated metabolites of vitamin D and dietary phosphate restriction on bone disease in uraemic rats. Main J; Velasco N; Heyes SD; Whiting P; Fraser RA; Catto GR Clin Sci (Lond); 1986 Nov; 71(5):539-43. PubMed ID: 3490349 [TBL] [Abstract][Full Text] [Related]
11. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Gallieni M; Kamimura S; Ahmed A; Bravo E; Delmez J; Slatopolsky E; Dusso A Am J Physiol; 1995 Apr; 268(4 Pt 2):F746-53. PubMed ID: 7733332 [TBL] [Abstract][Full Text] [Related]
12. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency. Soliman E; Canaff L; Fox J; Hendy GN Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053 [TBL] [Abstract][Full Text] [Related]
13. A possible direct effect of 24,25-dihydroxycholecalciferol on the parathyroid gland in patients with chronic renal failure. Christiansen C; Rødbro P; Naestoft J; Christensen MS Clin Endocrinol (Oxf); 1981 Sep; 15(3):237-42. PubMed ID: 6273028 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Kimura Y; Nakayama M; Kuriyama S; Watanabe S; Kawaguchi Y; Sakai O Clin Nephrol; 1991 Feb; 35(2):72-7. PubMed ID: 2019017 [TBL] [Abstract][Full Text] [Related]
15. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure. Lu KC; Lin SH; Yu FC; Chyr SH; Shieh SD Miner Electrolyte Metab; 1995; 21(6):398-402. PubMed ID: 8592483 [TBL] [Abstract][Full Text] [Related]
16. Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. Halloran BP; Schaefer P; Lifschitz M; Levens M; Goldsmith RS J Clin Endocrinol Metab; 1984 Dec; 59(6):1063-9. PubMed ID: 6333430 [TBL] [Abstract][Full Text] [Related]
17. Effect of uremic serum on 1,25-dihydroxyvitamin D3-induced differentiation of human promyelocytic leukemia cell, HL-60. Inaba M; Okuno S; Koyama H; Ishimura E; Nishizawa Y; Morii H Nephron; 1993; 63(2):152-8. PubMed ID: 8383808 [TBL] [Abstract][Full Text] [Related]
18. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol. Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673 [TBL] [Abstract][Full Text] [Related]
19. Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. Jones CL; Vieth R; Spino M; Ledermann S; Kooh SW; Balfe J; Balfe JW Clin Nephrol; 1994 Jul; 42(1):44-9. PubMed ID: 7923966 [TBL] [Abstract][Full Text] [Related]
20. Effect of dihydroxylated metabolites of vitamin D3 on calcium absorption in uraemic man. Muirhead N; Catto GR; Gvozdanovic S; Gvozdanovic D; Edward N Clin Sci (Lond); 1981 Dec; 61(6):723-7. PubMed ID: 6975197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]